Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study

Figures & data

Figure 1. Percentage of PASI score reduction at the last available visit of our 16 patients. Blue bars: patients treated with risankizumab; Green bars: patients treated with gulsekumab; Purple bars: patients treated with tildrakizumab. PASI: Psoriasis Area and Severity Index.

Table 1. Demographic and clinical characteristics of our patients.

Patient N.	Gender	Age (years)	Comorbidities	Current biological drug	TB prophylaxis	Follow-up duration (months)	PASI at baseline	PASI at last available observation
1	M	74	AH	Risankizumab	Yes	7.2	18	0
2	M	66		Risankizumab	No	33.6	24	0
3	M	52	AH	Tildrakizumab	Yes	9.2	12	0
4	M	29		Risankizumab	No	32.3	15	2
5	M	74		Guselkumab	Yes	8.6	7.5	0
6	M	63	AH	Risankizumab	No	43.8	17	0.5
7	M	40		Risankizumab	No	27.3	14	0
8	M	78	T2D	Guselkumab	Yes	34.2	10	2
9	M	55		Risankizumab	Yes	21.1	8	0
10	F	54		Risankizumab	No	26.00	12	0
11	M	74	AH	Guselkumab	Yes	23.6	15	0
12	M	63	AH	Risankizumab	Yes	8.2	12	0.8
13	F	61		Tildrakizumab	No	6.30	10	1
14	M	76		Risankizumab	Yes	11.0	20	5.8
15	M	65		Risankizumab	Yes	12.1	7	0
16	F	64		Risankizumab	Yes	16.57	10	0

PASI: Psoriasis Area and Severity Index; AH: Arterial Hypertension; T2D: Type 2-Diabetes.

Data availability statement

Data available on request from the authors.